Batimastat (BB94)

Description: Batimastat (formerly known as BB-94), a synthetic hydroxamate analog and an anticancer drug developed by Laurie Hines of British Biotech, is a broad spectrum inhibitor of matrix metalloprotease (MMP) with potential antitumor activity. It inhibits MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3 with IC50 of 3 nM, 4 nM, 4 nM, 6 nM and 20 nM, respectively. It also inhibits the activitity of other metalloproteases, such as ADAM17. It exhibits antineoplastic and antiangiogenic activity in various tumor models, including ovarian carcinoma xegnografts and human colon tumor.

References: Int J Cancer. 1994 Aug 1; 58(3):460-4; Cancer Res. 1994 Sep 1; 54(17):4726-8.

Related CAS #: 130464-84-5(sodium) 130370-60-4 (free base)

IUPAC/Chemical Name: (2S, 3R)-N-Hydroxy-N'-[(2S)-1-methylamino-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide.

InChi Key: XFILPEOLDIKJHX-QYZOEREBSA-N

InChi Code: InChI=1S/C23H31N3O4S2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11, 15, 17-19, 30H, 12-14H2, 1-3H3, (H, 24, 29)(H, 25, 27)(H, 26, 28)/t17-, 18+, 19+/m1/s1

SMILES Code: O=C(NO)[CH](CSC1=CC=CS1)[CH](CC(C)C)C(N[CH](CC2=CC=CC=C2)C(NC)=O)=O